Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

Fig. 2

Kaplan–Meier curves for overall survival. The median overall survival was 17.7 months (95% CI, 16.2–18.6) for CET vs. 11.7 months (95% CI, 10.4–12.8) for BEV (HR, 0.63; 95% CI, 0.44–0.89; p=0.007). Significant differences were detected in the overall survival between groups. *The hazard ratio was calculated using a Cox proportional hazards model, with age, the site of the primary tumour, the number of metastatic sites, serum lactate dehydrogenase level, portal vein invasion, duration of treatment, and the performance status as covariates and CET or BEV therapy as the time-dependent factor

Back to article page
\